// App-Quantinova.ai

: Dutch ALL11 Study: Improved Outcome for Acute Lymphoblastic Leukemia By Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for ETV6::RUNX1, Down Syndrome and Prednisone Poor Responders

Researchers

Presenter

  • Rob Pieters

Principal Investigators

  • Hester A. de Groot-Kruseman

  • Femke Verwer

  • Merian van Overveld

  • Edwin Sonneveld

  • Marta Fiocco

  • Vincent H.J. van der Velden

  • Berna Beverloo

  • Marc Bierings

  • Valerie de Haas

  • Peter M. Hoogerbrugge

  • Inge M. van der Sluis

  • Wim J.E. Tissing

  • Margreet Veening

  • Judith M. Boer

  • Monique L. den Boer

Medical Centers

  • Medical Statistics Section, Department of Biomedical Data Science, Leiden University Medical Center, Leiden, Netherlands

  • Dutch Childhood Oncology Group (DCOG), Utrecht, Netherlands

  • Department of Immunology, Erasmus University Medical Center, Rotterdam, Netherlands

  • Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands

  • Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, Netherlands

  • Dutch Childhood Oncology Group, Netherlands, Utrecht, Netherlands

  • Mathematical Institute, Leiden University, Leiden, Netherlands

Locations

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Down syndrome

Biomarkers

  • Breakpoint Cluster Region

  • ETV6-RUNX1

Drug/Treatment

  • Prednisone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved